Also found in: Dictionary.
Related to Avandia: Vioxx, metformin

rosiglitazone maleate


Pharmacologic class: Thiazolidinedione

Therapeutic class: Hypoglycemic

Pregnancy risk category C


Inhibits alpha-glucosidases, enzymes that convert oligosaccharides and disaccharides to glucose. This inhibition lowers blood glucose level, especially in postprandial hyperglycemia.


Tablets: 2 mg, 4 mg, 8 mg

Indications and dosages

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are either already taking rosiglitazone or not already taking rosiglitazone and are unable to achieve adequate glycemic control on other antidiabetics and, in consultation with their healthcare provider, have decided not to take pioglitazone for medical reasons

Adults: 4 mg P.O. once daily or 2 mg b.i.d. After 8 to 12 weeks, may increase to 8 mg daily or 4 mg b.i.d. if needed.

Off-label uses

• Polycystic ovary syndrome


• Established New York Heart Association (NYHA) Class III or IV heart failure


Use cautiously in:

• diabetic ketoacidosis, type 1 (insulin-dependent) diabetes mellitus (use not recommended)

• edema, NYHA Class I and II heart failure, elevated liver enzymes, jaundice

• concurrent use of insulin (not recommended)

• pregnant patients

• breastfeeding patients (use not recommended)

• children (safety and efficacy not established).


Obtain liver enzyme results before starting drug. Be aware that therapy shouldn't be initiated in patient with elevated baseline liver enzyme levels (alanine aminotransferase [ALT] level greater than 2.5 times the upper limit of normal) or if patient exhibits clinical evidence of active liver disease.

• Give with or without food.

• Be aware that drug is active only in presence of endogenous insulin and thus is ineffective in diabetic ketoacidosis or type 1 diabetes mellitus.

Adverse reactions

CNS: fatigue, headache

CV: hypertension, heart failure, increased risk of myocardial infarction

EENT: macular edema, decreased visual acuity, nasopharyngitis

GI: diarrhea

GU: menstrual dysfunction

Hematologic: anemia

Metabolic: hyperglycemia, hypoglycemia

Musculoskeletal: back pain, arthralgia, increased risk of fracture

Respiratory: upper respiratory infection

Other: edema, injury, weight gain


Drug-drug. CYP2C8 inducers (such as rifampin): decreased rosiglitazone area under the curve (AUC)

CYP2C8 inhibitors (such as gemfibrozil): increased rosiglitazone AUC

Drug-diagnostic tests. Free fatty acids, high-density lipoproteins, liver enzymes, low-density lipoproteins, total cholesterol: increased levels

Hematocrit, hemoglobin: decreased levels

Patient monitoring

• Monitor CBC, lipid panel, blood glucose, and glycosylated hemoglobin levels.

• Monitor patient's weight. Assess for fluid retention, which may lead to heart failure. Be aware that dosage increases should be accompanied by careful monitoring for adverse reactions related to fluid retention.

Closely monitor liver function tests. Be aware that patients with mildly elevated liver enzymes (ALT level 2.5 times ULN) at baseline or during therapy should be evaluated to determine cause of the liver enzyme elevation and if liver enzyme elevation resolves or worsens. If at any time ALT level increases to more than 3 times ULN, recheck liver enzyme levels as soon as possible. If ALT level remains at 3 times ULN, discontinue drug. If jaundice occurs, discontinue drug.

Patient teaching

• Tell patient he may take with or without food.

• Advise patient to monitor blood glucose level regularly and report significant changes.

Inform patient that drug may increase fluid retention, causing or exacerbating heart failure. Encourage him to weigh himself regularly and report sudden weight gain, swelling, or shortness of breath.

Teach patient to recognize and immediately report signs and symptoms of heart attack or liver problems.

• Tell patient to promptly report vision changes.

• Tell patient he'll undergo regular blood testing during therapy.

• Advise female patient that drug may result in ovulation in some premenopausal anovulatory women. Inform patient she may be at increased risk for pregnancy while taking this drug; recommend adequate contraception.

• Caution female patient not to breastfeed during therapy.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests and herbs mentioned above.


A trademark for the drug rosiglitazone maleate.


a trademark for an oral antidiabetic (rosiglitazone).


Rosiglitazone Diabetes An agent used with conventional therapy as a first-line monotherapy for type 2 diabetes. See Type 2 diabetes.
References in periodicals archive ?
In November 2007 the FDA extended the warning to cover an increased risk for myocardial infarction, based on "a meta-analysis of 42 clinical studies (mean duration 6 months; 14,237 total patients), most of which compared Avandia to placebo, and showed Avandia to be associated with an increased risk of myocardial ischemic events such as angina or myocardial infarction.
The agency, following its review of a large clinical trial (called Record) aimed at determining the drug's heart safety, said it found that the trial showed no elevated risk of heart attack or death in patients being treated with Avandia when compared with standard-of-care diabetes drugs.
The company noted that it does not accept any wrongdoing with the marketing of Avandia, and the settlement is to avoid lengthy trials.
He developed diabetes 20 years ago and was prescribed Avandia in 2003 but stopped when a report revealed users had a 43 per cent increased risk of potentially fatal heart problems.
As part of the settlement, the pharmaceutical company is admitting to promoting the drugs Paxil and Wellbutrin for off-label uses and failing to report safety data about Avandia to the Food and Drug Administration.
GSK also has spent more than $700 million to resolve patient lawsuits claiming Avandia caused heart attacks and strokes.
5bn in its last financial year to cover long-standing legal claims, including many relating to its controversial diabetes drug Avandia, which was taken off the market in Europe following allegations it increased risks of heart attack.
If the FDA had been aware of the increased cardiovascular risk that arises from drugs that cause fluid retention, Vioxx, Bextra, and Avandia might never have been approved.
The story of the approval of Avandia over the objection of agency medical reviewers (and FDA defense of the drug for more than a decade) reveals precisely why the agency cannot be counted upon to protect the American public.
European regulators last month suspended Avandia and further restrictions were placed on its US sales following evidence linking the treatment to an increased risk of heart attack.
MUSCAT: Avandia (Rosiglitazone Maleate), the anti-diabetes drug produced by GlaxoSmithKline (GSK), has been withdrawn from the Omani market.
PEOPLE with diabetes taking the drug Avandia have been told to contact their doctor urgently.